Personalis Cash on Hand 2018-2024 | PSNL

Personalis cash on hand from 2018 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Personalis Annual Cash on Hand
(Millions of US $)
2023 $114
2022 $168
2021 $287
2020 $203
2019 $128
2018 $20
2017 $
Personalis Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $144
2024-06-30 $87
2024-03-31 $95
2023-12-31 $114
2023-09-30 $121
2023-06-30 $137
2023-03-31 $149
2022-12-31 $168
2022-09-30 $193
2022-06-30 $233
2022-03-31 $267
2021-12-31 $287
2021-09-30 $305
2021-06-30 $329
2021-03-31 $353
2020-12-31 $203
2020-09-30 $206
2020-06-30 $105
2020-03-31 $120
2019-12-31 $128
2019-09-30 $127
2019-06-30 $163
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.261B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00